{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:27:14Z","timestamp":1769606834763,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T00:00:00Z","timestamp":1447804800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1245\/s10434-015-4969-2","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T14:21:23Z","timestamp":1447856483000},"page":"1096-1103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Australian Multicenter Study of Isolated Limb Infusion for Melanoma"],"prefix":"10.1245","volume":"23","author":[{"given":"Hidde M.","family":"Kroon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendon J.","family":"Coventry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell H.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Speakman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Serpell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Paddle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander G. J.","family":"Coventry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard Mark","family":"Smithers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,18]]},"reference":[{"key":"4969_CR1","unstructured":"Australian Institute of Health and Welfare, and Australasian Association of Cancer Registries 2012. Cancer in Australia: an overview, 2012. Australian Cancer Incidence and Mortality Workbooks-Melanoma. Cancer series no. 74. Cat. no. CAN 70. Canberra: Australian Institute of Health and Welfare; 2012."},{"key":"4969_CR2","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1245\/s10434-007-9717-9","volume":"15","author":"AB Francken","year":"2008","unstructured":"Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008;15:1476\u201384.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/jso.22029","volume":"104","author":"A Testori","year":"2011","unstructured":"Testori A, Faries MB, Thompson JF, et al. Local and intralesional therapy of in-transit\u00a0melanoma\u00a0metastases. J Surg Oncol. 2011;104:391\u20136.","journal-title":"J Surg Oncol."},{"key":"4969_CR4","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1634\/theoncologist.2009-0325","volume":"15","author":"D Moreno-Ramirez","year":"2010","unstructured":"Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, et al. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist. 2010;15:416\u201327.","journal-title":"Oncologist."},{"key":"4969_CR5","first-page":"188","volume":"7","author":"JF Thompson","year":"1994","unstructured":"Thompson JF, Waugh RC, Saw RPM, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188\u201392.","journal-title":"Reg Cancer Treat."},{"key":"4969_CR6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jso.21280","volume":"100","author":"HM Kroon","year":"2009","unstructured":"Kroon HM, Thompson JF. Isolated limb infusion: a review. J Surg Oncol. 2009;100:169\u201377.","journal-title":"J Surg Oncol."},{"key":"4969_CR7","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/cncr.24220","volume":"115","author":"HM Kroon","year":"2009","unstructured":"Kroon HM, Lin DY, Kam PC, et al. Efficacy of repeat isolated limb infusion with melphalan and actinomycin-D for recurrent melanoma. Cancer. 2009;115:1932\u201340.","journal-title":"Cancer."},{"key":"4969_CR8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/jso.23553","volume":"109","author":"HM Kroon","year":"2014","unstructured":"Kroon HM, Huismans AM, Kam PCA, et al. Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review. J Surg Oncol. 2014;109:348\u201351.","journal-title":"J Surg Oncol."},{"key":"4969_CR9","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1245\/s10434-008-9954-6","volume":"15","author":"HM Kroon","year":"2008","unstructured":"Kroon HM, Moncrieff M, Kam PC, et al. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15:3003\u201313.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR10","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jamcollsurg.2008.12.019","volume":"208","author":"GM Beasley","year":"2009","unstructured":"Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208:706\u201315.","journal-title":"J Am Coll Surg."},{"key":"4969_CR11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1245\/s10434-012-2782-8","volume":"20","author":"J Wong","year":"2013","unstructured":"Wong J, Chen YA, Fisher KJ, et al. Isolated limb infusion in a series of over infusions: a single-center experience. Ann Surg Oncol. 2013;20:1121\u20137.","journal-title":"Ann Surg Oncol"},{"key":"4969_CR12","first-page":"564","volume":"178","author":"JM Klaase","year":"1994","unstructured":"Klaase JM, Kroon BB, van Geel AN, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg. 1994; 178:564\u201372.","journal-title":"J Am Coll Surg."},{"key":"4969_CR13","first-page":"429","volume-title":"Textbook of Melanoma","author":"JF Thompson","year":"2004","unstructured":"Thompson JF, Kam PCA, de Wilt JHW, et al. Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz; 2004: pp. 429\u201337."},{"key":"4969_CR14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/jso.23540","volume":"109","author":"HM Kroon","year":"2014","unstructured":"Kroon HM, Huismans AM, Kam PCA, et al. Isolated limb infusion: technical aspects. J Surg Oncol. 2014;109:352\u20136.","journal-title":"J Surg Oncol."},{"key":"4969_CR15","first-page":"243","volume":"5","author":"MH Giles","year":"2013","unstructured":"Giles MH, Coventry BJ. Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit. Cancer Manag Res. 2013;5:243\u20139.","journal-title":"Cancer Manag Res."},{"key":"4969_CR16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","volume":"18","author":"J Wieberdink","year":"1982","unstructured":"Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905\u201310.","journal-title":"Eur J Cancer Clin Oncol."},{"key":"4969_CR17","first-page":"36","volume":"6","author":"DTM Lai","year":"1993","unstructured":"Lai DTM, Ingvar C, Thompson JF. The value of monitoring serum creatine phosphokinase values following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat. 1993;6:36\u20139.","journal-title":"Reg Cancer Treat."},{"key":"4969_CR18","unstructured":"World Health Organization. WHO handbook for reporting results of cancer treatments. WHO Offset Publication No. 48. Geneva: World Health Organization; 1979."},{"key":"4969_CR19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"L Kaplan","year":"1985","unstructured":"Kaplan L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1985;53:457\u201381.","journal-title":"J Am Stat Assoc."},{"key":"4969_CR20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life table. J Stat Soc. 1972;34:187\u2013220.","journal-title":"J Stat Soc."},{"key":"4969_CR21","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1245\/s10434-011-1646-y","volume":"18","author":"AM Huismans","year":"2011","unstructured":"Huismans AM, Kroon HM, Kam PC, et al. Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution. Ann Surg Oncol. 2011;18:1877\u201383.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/jso.23590","volume":"109","author":"BJ Coventry","year":"2014","unstructured":"Coventry BJ, Kroon HM, Giles MH, et al. Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. J Surg Oncol. 2014;109:780\u20135.","journal-title":"J Surg Oncol."},{"key":"4969_CR23","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1002\/cncr.27676","volume":"118","author":"GM Beasley","year":"2012","unstructured":"Beasley GM, Sharma K, Wong J, et al. A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. Cancer. 2012;118:6136\u201343.","journal-title":"Cancer."},{"key":"4969_CR24","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1245\/s10434-009-0717-9","volume":"16","author":"AP Barbour","year":"2009","unstructured":"Barbour AP, Thomas J, Suffolk J, et al. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol. 2009;16:3463\u201372.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1067\/j.cpsurg.2011.02.002","volume":"48","author":"A Sanki","year":"2011","unstructured":"Sanki A, Kroon HM, Kam PCA, et al. Isolated limb perfusion and isolated limb infusion for malignant lesions of the extremities. Curr Probl Surg. 2011;48:371\u2013430.","journal-title":"Curr Probl Surg."},{"key":"4969_CR26","first-page":"410","volume-title":"Textbook of melanoma","author":"BC Vrouenraets","year":"2004","unstructured":"Vrouenraets BC, Kroon BBR, Nieweg OE, et al. Isolated limb perfusion for melanoma: results and complications, toxicity. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz; 2004: pp. 410\u201328."},{"key":"4969_CR27","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1245\/s10434-009-0323-x","volume":"16","author":"HM Kroon","year":"2009","unstructured":"Kroon HM, Moncrieff M, Kam PC, et al. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol. 2009;16:1184\u201392.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR28","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1245\/s10434-009-0563-9","volume":"16","author":"AA Santillan","year":"2009","unstructured":"Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol. 2009;16:2570\u20138.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-3-642-74818-9_33","volume-title":"Progress in Regional Cancer Therapy","author":"RN Scott","year":"1990","unstructured":"Scott RN, Blackie R, Kerr DJ, et al. Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect. In: Jakesz R, Rainer H, editos. Progress in regional cancer therapy. Berlin: Springer; 1990: pp. 195\u2013200."},{"key":"4969_CR30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/bjc.1994.266","volume":"70","author":"JM Klaase","year":"1994","unstructured":"Klaase JM, Kroon BBR, Beijnen JH, et al. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer. 1994;70:151\u20133.","journal-title":"Br J Cancer."},{"key":"4969_CR31","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1245\/s10434-012-2316-4","volume":"19","author":"AM Huismans","year":"2012","unstructured":"Huismans AM, Kroon HM, Haydu LE, et al. Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma? Ann Surg Oncol. 2012;19:3050\u20136.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR32","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1245\/s10434-008-0288-1","volume":"16","author":"N McMahon","year":"2009","unstructured":"McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight\u00a0alter regional response or toxicity? Ann Surg Oncol. 2009;16:953\u201361.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0360-3016(91)90106-E","volume":"20","author":"DW Siemann","year":"1991","unstructured":"Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys. 1991;20:287\u20139.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"4969_CR34","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/bjc.1997.200","volume":"75","author":"ZY Wu","year":"1997","unstructured":"Wu ZY, Smithers BM, Parsons PG, et al. The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. Br J Cancer. 1997;75:1160\u20136.","journal-title":"Br J Cancer."},{"key":"4969_CR35","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1200\/JCO.1998.16.9.2906","volume":"16","author":"HS Koops","year":"1998","unstructured":"Koops HS, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. J Clin Oncol. 1998;16:2906\u201312.","journal-title":"J Clin Oncol."},{"key":"4969_CR36","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1245\/s10434-013-3336-4","volume":"21","author":"J Wong","year":"2014","unstructured":"Wong J, Ann Chen Y, Fisher KJ, et al. Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma. Ann Surg Oncol. 2014;21:650\u20135.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR37","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","volume":"22","author":"JF Thompson","year":"2015","unstructured":"Thompson JF, Agarwala SS, Smithers BM, et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015;22:2135\u201342.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jso.23506","volume":"109","author":"DL Damian","year":"2014","unstructured":"Damian DL, Saw RP, Thompson JF. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol. 2014;109:308\u201313.","journal-title":"J Surg Oncol."},{"key":"4969_CR39","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1245\/s10434-014-4072-0","volume":"22","author":"DJ Muilenburg","year":"2015","unstructured":"Muilenburg DJ, Beasley GM, Thompson ZJ, et al. Burden of disease predicts response to\u00a0isolated\u00a0limb\u00a0infusion with melphalan and actinomycin d in melanoma. Ann Surg Oncol. 2015;22:482\u20138.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR40","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1245\/s10434-012-2373-8","volume":"19","author":"GM Beasley","year":"2012","unstructured":"Beasley GM, Coleman AP, Raymond A, et al. A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. Ann Surg Oncol. 2012;19:3896\u2013905.","journal-title":"Ann Surg Oncol."},{"key":"4969_CR41","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2010.32.1224","volume":"29","author":"GM Beasley","year":"2011","unstructured":"Beasley GM, Riboh JC, Augustine CK, et al. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. J Clin Oncol. 2011;29:1210\u20135.","journal-title":"J Clin Oncol."},{"key":"4969_CR42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/CMAR.S31887","volume":"4","author":"BJ Coventry","year":"2012","unstructured":"Coventry BJ, Ashdown ML. Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. Cancer Manag Res. 2012;4:137\u201349.","journal-title":"Cancer Manag Res."},{"key":"4969_CR43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/CMAR.S49494","volume":"6","author":"M Tronnier","year":"2014","unstructured":"Tronnier M, Mitteldorf C. Treating advanced melanoma: current insights and opportunities. Cancer Manag Res. 2014;6:349\u201356.","journal-title":"Cancer Manag Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-015-4969-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-015-4969-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-015-4969-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T14:45:47Z","timestamp":1718203547000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-015-4969-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,18]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["4969"],"URL":"https:\/\/doi.org\/10.1245\/s10434-015-4969-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,18]]}}}